zolbetuximab
astellas
[]
primary results from the phase 3 spotlight study just in from #gi23: zolbetuximab + mfolfox6 (vs placebo) as 1l treatment demonstrated statistically significant improvements in pfs and os, but similar orr. what does this mean for the future of cldn18.2-targeting agents? 